Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.
about
Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disordersReview of pharmacological treatment in mood disorders and future directions for drug development.Management of bipolar I depression: clinical utility of lurasidoneTargeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to DateCurrent investigational drugs for major depressionDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsPharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategyThe 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.The 5-HT7 receptor and disorders of the nervous system: an overview.Pharmacological blockade of serotonin 5-HT₇ receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders.Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortexModes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.5-HT7 receptor modulates GABAergic transmission in the rat dorsal raphe nucleus and controls cortical release of serotoninThe role of serotonin receptor subtypes in treating depression: a review of animal studiesFuture directions for serotonin and antidepressants.Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient miceAssessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).Classical neurotransmitters and neuropeptides involved in major depression: a review.Serotonin: from top to bottom.The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionNew design strategies for antidepressant drugs.Modulating the serotonin system in the treatment of major depressive disorder.The role of 5-HT receptors in depression.Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission.Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity.Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats.RETRACTED: Serotonin 5-HT7 receptor agonist, LP-211, exacerbates Na(+), K(+)-ATPase/Mg(2+)-ATPase imbalances in spinal cord-injured male rats.Converging evidence for central 5-HT effects in acute tryptophan depletion?The acute inhibition of rapid eye movement sleep by citalopram may impair spatial learning and passive avoidance in mice.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.Pharmacophore Comparison and Development of Recently Discovered Long Chain Arylpiperazine and Sulfonamide Based 5-HT7 Ligands.Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.Persistent modification of forebrain networks and metabolism in rats following adolescent exposure to a 5-HT7 receptor agonist.Whole genome sequencing of a dizygotic twin suggests a role for the serotonin receptor HTR7 in autism spectrum disorder.
P2860
Q24632508-37D22262-55AD-4362-9D9B-5B3D4458010AQ26853509-23B5B04B-0D09-470F-8CAB-451EAB772CE9Q27012673-0ED0E5DD-42B7-49C9-947C-72716976D770Q28084125-3F7F9250-6683-45F8-AA40-137F5C834276Q28244223-11DE7620-6229-44B7-9F13-E8828C12ABA7Q28305100-9781900E-0840-42DA-851A-E0CA9177118EQ30468153-2AE0D0F9-0A4C-4225-907B-3D65597CBE00Q33706833-8532FB8D-1BD8-4457-923D-9B56DFBA35E8Q33738349-CFC98F60-8A6C-409E-A50F-8C22C4E7F9A4Q33942069-6208702F-6BDC-42AC-8DDB-6B110FC99B90Q34093279-00CD2E8A-F8C2-4679-B57C-59F07138769CQ34172419-097BAAD0-48A0-4AC4-BD15-FA506E861923Q34268057-BC0ABF9B-0024-4B0B-AB96-4A3EB70BF590Q34669080-4190A701-F125-4366-A677-6331F25A81E5Q34671692-A2F614DE-2024-4DBB-B26C-1665A7EB340BQ35964136-E6973FC7-923A-4470-8C41-0FD01A7C9E22Q36031101-2559B899-6724-4096-A494-9E920FFC0DE3Q36540966-8E2B6DF4-78CA-4E0E-A989-F58024E8F9F9Q36975571-5B68747D-7334-4FD1-8987-2850AEA47A2BQ37206280-4FB75936-C8EE-4ABB-ACFD-8F118D655145Q37754465-70770024-A617-4ADB-AE94-A2C95EB165C1Q37768172-E3A84B50-4104-4703-B1D5-00C6D4FEA125Q38055710-0EFD0137-224A-4786-A383-EEED4D6E83D5Q38120295-544804AE-A6C5-4B93-BC76-954E54FD9113Q38125568-FD50EDD6-CDEE-43C4-83A4-0F4378BC31D5Q38132807-44443F76-D928-4887-A8BE-2D9A597E6186Q38301941-5C2C19E0-A73F-440C-8E79-8088CA62BD50Q39395776-08D10C2A-517E-4061-B8E4-92D1FDE290B0Q39640436-5514159D-A4D2-4A98-BB34-15220F4EB04CQ41440051-950DDD47-4B15-4FDD-B020-F5B16B6B7D33Q41841409-B93587B1-1488-427C-9A95-2B6B51E599A1Q41940746-487031DF-FF3B-4D70-B5AB-BF551A7299BBQ42129572-68C2B72F-AFB6-4C77-A1C8-19720A45D559Q43789633-0DCCD4FE-EB55-40C3-AEC9-85B67A03FF7BQ44428816-90190289-ECAE-4D93-958C-9F603EEB7345Q47382890-D88E7BD6-8CA7-4CE9-88EC-5EBD567E6A16Q47770513-64475638-02ED-4268-B88C-6D2EF5A9A0E9Q48066819-86D80AB4-1335-46C9-B0B4-C1004CE01227Q48100455-4FD41907-0D2C-4269-A98F-07CBFA7D2285Q48638262-E36B3E95-F00B-4E03-BEE1-0C09BFB56BDA
P2860
Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@ast
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@en
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@nl
type
label
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@ast
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@en
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@nl
prefLabel
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@ast
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@en
Selective blockade of 5-hydrox ...... uced by citalopram in rodents.
@nl
P2093
P356
P1476
Selective blockade of 5-hydrox ...... duced by citalopram in rodents
@en
P2093
Brian Lord
Christine Dugovic
Jonathan Shelton
Kirsten Miller
Leah Aluisio
Lisa Kelly
Pascal Bonaventure
Ruggero Galici
Timothy W Lovenberg
P304
P356
10.1124/JPET.107.119404
P407
P50
P577
2007-02-21T00:00:00Z